CORC

浏览/检索结果: 共2条,第1-2条 帮助

限定条件                    
已选(0)清除 条数/页:   排序方式:
Efficacy, safety, and pharmacokinetics of the anti-programmed cell death receptor-1 (PD-1) monoclonal antibody, tislelizumab (BGB-A317) in a phase 2, open-label, multicenter study to investigate in patients with unresectable hepatocellular carcinoma - Trial in progress 会议论文
作者:  Ren, Z.;  Assenat, E.;  Cubillo, A.;  Pluntke, S.;  Rimassa, L.
收藏  |  浏览/下载:11/0  |  提交时间:2019/12/05
A randomized multicentered phase II study to evaluate SHR-1210 (PD-1 antibody) in subjects with advanced hepatocellular carcinoma (HCC) who failed or intolerable to prior systemic treatment 会议论文
作者:  Qin, S. K.;  Ren, Z. G.;  Meng, Z. Q.;  Chen, Z. D.;  Chai, X. L.
收藏  |  浏览/下载:6/0  |  提交时间:2019/12/05


©版权所有 ©2017 CSpace - Powered by CSpace